These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34651447)

  • 21. Discovery of the potent covalent inhibitor with an acrylate warhead for SARS-CoV-2 3CL protease.
    Shen W; Chen X; Zhou L; Cheng Y; Zhang Y; Jiang X; Sun H; Shen J
    Bioorg Med Chem Lett; 2024 Nov; 112():129942. PubMed ID: 39218405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
    Hajbabaie R; Harper MT; Rahman T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV.
    Park JY; Ko JA; Kim DW; Kim YM; Kwon HJ; Jeong HJ; Kim CY; Park KH; Lee WS; Ryu YB
    J Enzyme Inhib Med Chem; 2016; 31(1):23-30. PubMed ID: 25683083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of SARS-CoV-2 main protease inhibitors using a synthesis-directed
    Morris A; McCorkindale W; Consortium TCM; Drayman N; Chodera JD; Tay S; London N; Lee AA
    Chem Commun (Camb); 2021 Jun; 57(48):5909-5912. PubMed ID: 34008627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening.
    Abian O; Ortega-Alarcon D; Jimenez-Alesanco A; Ceballos-Laita L; Vega S; Reyburn HT; Rizzuti B; Velazquez-Campoy A
    Int J Biol Macromol; 2020 Dec; 164():1693-1703. PubMed ID: 32745548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
    Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
    Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
    Huff S; Kummetha IR; Tiwari SK; Huante MB; Clark AE; Wang S; Bray W; Smith D; Carlin AF; Endsley M; Rana TM
    J Med Chem; 2022 Feb; 65(4):2866-2879. PubMed ID: 34570513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2.
    Drayman N; DeMarco JK; Jones KA; Azizi SA; Froggatt HM; Tan K; Maltseva NI; Chen S; Nicolaescu V; Dvorkin S; Furlong K; Kathayat RS; Firpo MR; Mastrodomenico V; Bruce EA; Schmidt MM; Jedrzejczak R; Muñoz-Alía MÁ; Schuster B; Nair V; Han KY; O'Brien A; Tomatsidou A; Meyer B; Vignuzzi M; Missiakas D; Botten JW; Brooke CB; Lee H; Baker SC; Mounce BC; Heaton NS; Severson WE; Palmer KE; Dickinson BC; Joachimiak A; Randall G; Tay S
    Science; 2021 Aug; 373(6557):931-936. PubMed ID: 34285133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses.
    Wang R; Zhai G; Zhu G; Wang M; Gong X; Zhang W; Ge G; Chen H; Chen L
    Bioorg Chem; 2023 Jan; 130():106264. PubMed ID: 36395603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL
    Rawson JMO; Duchon A; Nikolaitchik OA; Pathak VK; Hu WS
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33498923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
    Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
    Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CL
    Wang R; Hu Q; Wang H; Zhu G; Wang M; Zhang Q; Zhao Y; Li C; Zhang Y; Ge G; Chen H; Chen L
    Int J Biol Macromol; 2021 Jul; 183():182-192. PubMed ID: 33901557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-acylbenzimidazoles as selective Acylators of the catalytic cystein of the coronavirus 3CL protease.
    Chaibi FZ; Brier L; Carré P; Landry V; Desmarets L; Tarricone A; Cantrelle FX; Moschidi D; Herledan A; Biela A; Bourgeois F; Ribes C; Ikherbane S; Malessan M; Dubuisson J; Belouzard S; Hanoulle X; Leroux F; Deprez B; Charton J
    Eur J Med Chem; 2024 Oct; 276():116707. PubMed ID: 39068863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3-chymotrypsin-like protease in SARS-CoV-2.
    Al Adem K; Ferreira JC; Villanueva AJ; Fadl S; El-Sadaany F; Masmoudi I; Gidiya Y; Gurudza T; Cardoso THS; Saksena NK; Rabeh WM
    Biosci Rep; 2024 Aug; 44(8):. PubMed ID: 39036877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ensemble Docking Coupled to Linear Interaction Energy Calculations for Identification of Coronavirus Main Protease (3CL
    Jukič M; Janežič D; Bren U
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33316996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re
    Karges J; Kalaj M; Gembicky M; Cohen SM
    Angew Chem Int Ed Engl; 2021 May; 60(19):10716-10723. PubMed ID: 33606889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
    Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
    Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
    Amin SA; Banerjee S; Ghosh K; Gayen S; Jha T
    Bioorg Med Chem; 2021 Jan; 29():115860. PubMed ID: 33191083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-Guided Design of Potent Inhibitors of SARS-CoV-2 3CL Protease: Structural, Biochemical, and Cell-Based Studies.
    Dampalla CS; Rathnayake AD; Perera KD; Jesri AM; Nguyen HN; Miller MJ; Thurman HA; Zheng J; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Kim Y; Groutas WC; Chang KO
    J Med Chem; 2021 Dec; 64(24):17846-17865. PubMed ID: 34865476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.